24 March 2025 - results
The AIM-listed manufacturer and distributor of rapid tests in the healthcare sector has announced interim results for the six months to 31 December 2024 and these have shown a 28% increase in revenues to £3.1m (2023: £2.4m). The adjusted pre-tax loss rose to £2.2m (2023: loss of £1.5m) due to a significant investment in operations including the opening of new laboratories in Doncaster and Madison, Wisconsin, USA. The group had cash at 31 December of £3.7m (30 June 2024: £1.4m) following the investment into its operations and the . . .
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.
